API SUPPLIERS

API Suppliers

0

US DMFs Filed

0

CEP/COS Certifications

0

JDMFs Filed

0

EU WC

0

Listed Suppliers

0

API REF. PRICE (USD / KG)

0

API Market Place

0

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

0

Europe

0

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Full Screen View

NephroDI Therapeutics

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

NephroDI Therapeutics Enters Agreement to Develop a First-in-Class Treatment for a Genetic, Rare Disease of the Kidneys

Details:

The agreement aims for the clinical development of NephroDI’s asset, NDI-5001, a novel kidney-targeted small molecule AMPK activator, as a potential therapy for X-linked congenital Nephrogenic Diabetes Insipidus (NDI).

Lead Product(s): NDI-5001

Therapeutic Area: Rare Diseases and Disorders Product Name: NDI-5001

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: McQuade Center for Strategic Research and Development

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 22, 2023

ASK
US

Upload
your Marketing & Sales content

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Find Drugs in Development News & Deals for NDI-5001

NDI-5001